Poor compliance with conventional asthma medications remains a major problem in achieving asthma control. Nigella sativa oil (NSO) is used traditionally for many inflammatory conditions such as asthma. We aimed to investigate the benefits of NSO supplementation on clinical and inflammatory parameters of asthma. NSO capsules 500 mg twice daily for 4 weeks were used as a supplementary treatment in a randomized, double-blind, placebo-controlled trial in asthmatics (clinicaltrials.gov: NCT02407262). The primary outcome was Asthma Control Test score. The secondary outcomes were pulmonary function test, blood eosinophils and total serum Immunoglobulin E. Between 1 June and 30 December 2015, 80 asthmatics were enrolled, with 40 patients in each treatment and placebo groups. After 4 weeks, ten patients had withdrawn from each group. Compared with placebo, NSO group showed a significant improvement in mean Asthma Control Test score 21.1 (standard deviation = 2.6) versus 19.6 (standard deviation = 3.7) (p = 0.044) and a significant reduction in blood eosinophils by À50 (À155 to À1) versus 15 (À60 to 87) cells/μL (p = 0.013). NSO improved forced expiratory volume in 1 second as percentage of predicted value by 4 (À1.25 to 8.75) versus 1 (À2 to 5) but non-significant (p = 0.170). This randomized, double-blind, placebo-controlled trial demonstrated that NSO supplementation improves asthma control with a trend in pulmonary function improvement. This was associated with a remarkable normalization of blood eosinophlia. Future studies should follow asthmatics for longer periods in a multicentre trial. Copyright
INTRODUCTION
Asthma control is considered to be suboptimal regardless of the availability of conventional treatments (Demoly et al., 2012; Price et al., 2014) . Data from the Recognise Asthma and Link to Symptoms and Experience survey in 2014 for 8000 European patients revealed that the level of asthma control remains low (Price et al., 2014) .
A key concern is poor adherence to asthma medications (Horne et al., 2007; Haughney et al., 2008) . Common medication-related reasons for non-adherence include difficulties with using inhaler techniques, the complex course of therapy, adverse events and cost of medications (Bateman et al., 2008; Dima et al., 2015) .
The Global Asthma Physician and Patient (GAPP) Survey reported that 39% of asthma patients exchanged or stopped their asthma medication because of adverse events (GAPP, 2005) . A total of 76% of patients and 81% of physicians consider that new treatment options are required (GAPP, 2005) . The introduction of novel treatment strategies (such as 'add-on' treatments) is a key step for better asthma control (Lommatzsch and Stoll, 2016) .
Up to 79% of adult patients with asthma used different complementary and alternative treatments including herbal medicines, but the evidence for such treatments' effectiveness in asthma is very limited (Slader et al., 2006) . A review of plant-based medicines used in asthma management found that the evidence is still unconvincing and there is a need for a proper scientific research to support the use of plant-based medicines in asthma (Clarke et al., 2015) . Therefore, phytotherapy remains a commonly used but poorly investigated element of asthma treatment.
Traditionally, Nigella sativa L. (NS; Ranunculaceae), known as black seed, is used as a food supplement or herbal medicine for a range of inflammatory diseases such as asthma (Lebling and Pepperdine, 2006) . A survey of 200 patients with asthma in Saudi Arabia found that 34.5% used unconventional therapies and NS was of the most common treatments recorded (Al Moamary, 2008) .
In several preclinical and preliminary clinical studies, NS and its main active compound thymoquinone (TQ) showed positive effects on clinical and biochemical markers of asthma inflammation. In mouse models of asthma, Nigella sativa oil (NSO) reduced airway hyperresponsiveness, total leukocytes, macrophages, eosinophils and serum levels of total Immunoglobulin E (IgE) (Balaha et al., 2012) . NSO reduced peripheral blood eosinophil count in conalbumin sensitized mice (Abbas et al., 2005) . NSO prevented inflammatory cell infiltration and pathological lesions in the lungs in ovalbumin sensitized rat (Shahzad et al., 2009) . TQ was able to reduce eosinophilia in ovalbumin sensitized mice (El Gazzar et al., 2006a) . In a randomized double-blind placebo-controlled trials (RDBPCTs), NS aqueous extract improved asthma symptoms and pulmonary function tests in 29 asthmatics (Boskabady et al., 2007) . In a randomized double-blind controlled trial, NS aqueous extract improved pulmonary function tests of 15 asthmatics (Boskabady et al., 2010) . In non-randomized open-label trial, NS combined with bee honey improved lung forced vital capacity in five asthmatics. In a randomized single-blind controlled trial, NS powder enhanced asthma control in combination with immunotherapy in 31 asthmatic children (Kardani et al., 2013) . However, these clinical trials had some limitations. First, sample size was limited to a maximum of 29 asthmatics. Second, the investigated outcomes were limited in the measurement of only symptoms, and pulmonary function except in one trial blood eosinophils and total serum IgE were investigated. However, they did not compare the results of these biomarkers with placebo. Third, limited information on the chemical composition and quality of the investigational NS preparation was used in most trials. Therefore, we aimed at conducting a clinical trial with a higher standard of trial design (RDBPCT) and sample size (more than 29 adult asthmatics), with inclusion of additional asthma biomarkers, and using chemically characterized preparation of NS.
MATERIAL AND METHODS
Trial design. The trial was prospective phase II randomized (1:1) double-blind placebo-controlled parallelgroup clinical trial (RDBPCT).
Participants. The inclusion criteria for patients were as follows: adult man/woman (age 18-65 years), asthma diagnosis based on the Global Initiative for Asthma guidelines (Global Initiative for Asthma, 2014), asthma symptoms not fully controlled based on Asthma Control Test (ACT) score from 5 to 24, no severe asthma exacerbation in the last 4 weeks and able to obtain consent.
The exclusion criteria were as follows: serious comorbid conditions, smoking history, pregnant women, taking any preparation containing NSO, known history of hypersensitivity to NSO and taking medications that may interact with NSO such as anticoagulant/ antiplatelet, CNS (central nervous system) depressants and immunosuppressants.
Study settings. The trial was conducted at medical clinics of respiratory, allergy and family medicine at King Abdulaziz University Hospital (KAUH), Jeddah, Saudi Arabia.
Ethical approval for the phase II RDBPCT was granted by both the ethical committees of University College London (ID: 6419/002) and King Abdulaziz University (ID: 95-15). Approval by the national regulatory framework of clinical trials in Saudi Arabia (Saudi Food and Drug Authority) was obtained. The trial was registered with the clinicaltrials.gov database, identifier NCT02407262 and The Saudi Clinical Trials Registry, identifier 15051902.
Interventions. In the treatment group, softgel capsules of cold-pressed NSO [0.7% TQ, analysed by highperformance liquid chromatography at our labs at the UCL School of Pharmacy, London, UK] were used. The treatment product is produced according to pharmaceutical good manufacturing practice standards by Marnys® (Cartagena, Spain; brand name: CUMINMAR; batch number: L885) and licensed as an herbal medicinal product in Saudi Arabia. The placebo group received similar capsules of virgin olive oil (produced in identical appearance by Marnys, batch number: M398). Both groups received a dose of one capsule (500 mg oil) twice daily for 4 weeks.
Outcomes. The primary outcome was the ACT score. The Global Initiative for Asthma guidelines recommends using one of the numerical asthma control tools such as ACT for scoring the level of asthma control and patients' progress (Global Initiative for Asthma, 2014) . ACT is one of the best-validated instruments to measure asthma control (Cloutier et al., 2012) . ACT consists of five questions in total scale of 5-25 with each question (Q1-Q5) scaled from one to five. Full control is determined as total ACT score of 25 (Nathan et al., 2004) . Questions of ACT are the following:
1. Q1 = In the past 4 weeks, how much of the time did your asthma keep you from getting as much done at work, school or at home? 2. Q2 = During the past 4 weeks, how often have you had shortness of breath? 3. Q3 = During the past 4 weeks, how often did your asthma symptoms (wheezing, coughing, shortness of breath, chest tightness or pain) wake you up at night or earlier than usual in the morning? 4. Q4 = During the past 4 weeks, how often have you used your rescue inhaler or nebulizer medication? 5. Q5 = How would you rate your asthma control during the past 4 weeks?
The secondary outcomes were pulmonary function test, absolute peripheral blood eosinophils count and total serum IgE.
Pulmonary function test was carried out using an Easy on-PC spirometer (ndd Medical Technologies, Switzerland).
Randomization and blinding. Both the investigator and the patients were blinded to treatment or placebo groups. An external medical scientist created a randomization list with Sealed Envelope Ltd online tool in random permuted blocks of sizes 2 and 4. These mixed block sizes were used to reduce the selection bias and achieve a better balance in the allocation of participants. The collaborating physicians enrolled participants from their clinics, and the investigator allocated patients to their concealed study medications. The packaging label of study medications contained the randomization code, study title, expiration date, date of packaging and contact information.
Procedures and compliance check. Patients were recruited from the respiratory, allergy and family medicine clinics at KAUH in Jeddah, Saudi Arabia, during the period of 1 June to 30 December 2015.
The study duration was 4 weeks for each patient. During the first visit and after signing the study consent form, patients' baseline demographics, symptoms, comorbid conditions and medications were recorded. The relevant study outcomes were evaluated, and the ACT was scored by the principal investigator by direct questioning of patients. Then, the study medication was dispensed to the patient. After 4 weeks, the patient returned for follow-up and was assessed for the completion of outcomes. During the treatment period, the principal investigator contacted patients by phone after the first week to check compliance and any appearance of side effects.
Blood sampling and biomarkers measurement. Venous blood samples were collected twice (at the baseline and follow-up visits) for the assessment of absolute peripheral blood eosinophils count and total serum IgE. Four millilitres fresh blood was used for blood eosinophils counting. Three milliners blood was used for total serum IgE testing. The blood analysis was carried out using the Celldyn-3500 counter (Abbot) at KAUH's haematology laboratory. This flow cytometry counter provides differential white blood cell counts automatically and used to measure blood eosinophil count. Total serum IgE was measured with the ImmunoCAP® total IgE (Phadia Laboratory Systems, Sweden) at the clinical immunology laboratory of KAUH.
Statistical analysis and sample size estimation. The study sample size (80) was calculated on the basis of the expected improvement in primary outcome (ACT) from an average score of 17 to 20 (effect size = 0.638, power = 80%, the level of statistical significance = 0.05 and two-sided independent t-test).
IBM SPSS STATISTICS 23 software was used for statistical data analysis. The normality of data was tested using Shapiro-Wilk test and Q-Q plot. Normally distributed data were represented as mean (standard deviation), and independent t-test was used to compare the means of the outcomes between two groups. However, nonnormal data were represented as median (interquartile range), and Mann-Whitney U-test was used. Intentionto-treat analysis was used for the primary outcome. Multiple regression-substitution was used for imputing primary outcome missing data, taking into account baseline values.
RESULTS

Subjects
A total of 140 patients with asthma were assessed for eligibility. Of them, 80 patients were randomized into treatment and placebo groups. In each group, ten patients did not complete the study. Reasons for dropout were variable mainly non-medical such as loss of interest and inability to attend. Only four patients had medical reasons such as adverse events and asthma exacerbation. The recruitment flow chart and details of dropout reasons are provided in Fig. 1 . The baseline demographics of the recruited patients are presented in Table 1 . Patients were on routine asthma medications that were adjusted and optimized according to Global Initiative for Asthma guidelines for standard asthma management (Global Initiative for Asthma, 2014). These included inhaled short-acting beta agonist (salbutamol), inhaled long-acting beta agonist (salmetrol or formetrol), inhaled corticosteroids (budesonide or fluticasone) and oral anti-leukotrienes (montelukast).
Asthma Control Test
At baseline, the average levels of symptoms control, represented by the total ACT score, were similar between the treatment and placebo groups. At the end of the study, the average total ACT score was significantly higher in the treatment group over the placebo group as shown in Table 2 . In addition to the total ACT score, the five individual parameters of ACT were also analysed. Significant improvement was found in the Q1 and Q2 of ACT. However, there was a positive improvement in the Q2, Q3 and Q4 of ACT but not statistically significant (Table 2) .
Pulmonary function test
At the end of the study, there was a trend for improvement in the percentage of predicted forced expiratory volume in 1 s (FEV1) and peak expiratory flow but not forced expiratory flow between 25% and 75% as shown in Table 3 . However, in subgroup analysis of patients with low basal predicted FEV1% (<80%), significant improvement was found in the treatment subgroup (n = 14) versus placebo subgroup (n = 15) by 8% (3-13%) versus 1% (À2 to 5%) (p = 0.018), respectively.
Blood outcomes
There was a marked significant reduction in the absolute peripheral blood eosinophil count in the treatment group compared with the placebo group by À50 (À155 Fig. 2 . On the other hand, there was no significant change found on the total serum IgE level between both groups as shown in Fig. 3 .
Safety and tolerability
Three patients (two from the treatment group and one from the placebo group) reported three adverse events including stomach upset, headache and insomnia. These adverse events were mild and self-limited (did not require any treatment or hospitalization). The study treatment is considered to be generally tolerable as only two patients (one from the treatment group and one from the placebo group) discontinued the study because of adverse events.
DISCUSSION
In this study, NSO significantly improved asthma control over placebo and showed a trend toward pulmonary function improvement with an acceptable safety and tolerability profile among adult asthmatic patients. Therefore, this study helps to build-up an evidence-base for using such supplements in the management of this disease. Unlike some other clinical trials, the chemical composition of the main active compound in NSO was determined by high-performance liquid chromatography analysis, and the product was good manufacturing practice certified.
Our findings in asthma symptoms control, measured by ACT, were consistent with symptoms improvement in previous clinical studies of NS in asthmatic patients. NSO enhanced scores of subjective improvement in clinical symptoms of allergic conditions including asthma (Kalus et al., 2003) . An aqueous extract of NS significantly improved the severity of asthma symptoms (Boskabady et al., 2007) . The administration of powdered NS among asthmatic children with immunotherapy significantly increased ACT scores (Sugiono et al., 2013) . In this study, there was a trend toward pulmonary function improvement in FEV1 and peak expiratory flow in the treatment group but did not reach statistical significance between the treatment and placebo groups as in previous studies. However, we found a significant improvement between both groups in pulmonary function only among subgroups of patients with below normal predicted FEV1% (<80%) at baseline. In a previous clinical study, an aqueous extract of NS significantly improved pulmonary function parameters between the treatment and placebo groups only after 3 months treatment, but all patients in this study had abnormal pulmonary function at baseline (Boskabady et al., 2007) . Also, an aqueous extract of NS caused a significant improvement in short-term pulmonary function parameters in 30 min until 150 min, but it was not compared with placebo, and all patients (15 asthmatic) had abnormal pulmonary function at baseline (Boskabady et al., 2010) . In non-randomized controlled trial open-label clinical study, NS seeds combined with bee honey improved pulmonary function, but this study was not placebo controlled and included only five asthmatics (Al Ameen et al., 2011) .
Interestingly, this study discovered a remarkable reduction of peripheral blood eosinophil count. Eosinophil cell plays a major role in asthma inflammation, and blood eosinophil count is considered to be a vital biomarker in asthma trials (Szefler et al., 2012) . To our knowledge, this is the first RDBPCT study that showed a significant reduction of blood eosinophilia by NSO among asthmatic patients.
The total IgE level in this study did not show any significant changes. This was consistent with findings of Kalus et al. (2003) who reported a non-significant IgE changes among NSO group, but this study including only three asthmatic patients was not statistically significant compared with placebo. However, in another clinical study, there was a significant reduction of serum total IgE in the group of NS, but this study was conducted in children, was not double-blinded placebo-controlled, and NS was combined with a probiotics and immunotherapy (Sugiono et al., 2013) . Several mechanisms of actions were suggested for NS or TQ, which may explain its effects in asthma. The aqueous extract of NS showed a competitive antagonistic activity on histamine H1 receptors (Boskabady and Sheiravi, 2002) . TQ inhibited leukotrienes (LTC4 and LTB4) synthesis in human blood cells (Mansour and Tornhamre, 2004) . TQ reduced leukotrienes (LTB4 and LTC4) levels by 5-lipoxygenase enzyme inhibition and decreased T-helper cell type 2 cytokines level in a mouse model of allergic asthma (El Gazzar et al., 2006b) . NSO was effective in decreasing histamine and leukotrienes production and increasing PGE2 (Prostaglandin E2) release in guineapig model of allergic asthma (Saleh et al., 2012) .
Limitations of our study include the following. The duration of the intervention is relatively short (4 weeks only). The choice of outcomes was dependent on its applicability and availability at the study site. A relatively high dropout rate that resulted from reasons not related to study design or medication, but rather due to unexpected reasons not considered initially including the geographical mobility of some of the study participants. In addition, the lack of incentives for participants (due to limited funding) along with the socioeconomic status of some the participants played a role in patient retention rate.
CONCLUSION
The NSO supplementation appeared to be effective in enhancing the control of asthma symptoms with a trend in pulmonary function improvement. Remarkably, NSO showed a reduction of blood eosinophilia. These findings may provide an evidence for the potential benefits of NSO supplementation in the clinical management of asthma. To our knowledge, this is the first RDBPCT that compared the effect of NSO on blood eosinophils and serum total IgE in a relatively larger group of adult patients with asthma versus placebo. Future studies should follow patients for a longer period and use additional outcomes to validate the benefits of NSO in asthma.
